Skip to content

Cardiovascular Risk Reduction

Cardiovascular risk reduction means lowering the likelihood of conditions affecting the heart and blood vessels. These conditions include coronary heart disease, peripheral arterial disease, aortic disease and stroke.

Altace

Ramipril

1.25mg · 2.5mg · 5mg · 10mg

Ramipril tablets for high blood pressure and heart failure. As an ACE inhibitor, it is also used to protect the kidneys in people with diabetes.

From$1.01/ tabletView

Empagliflozin Tablets

Empagliflozin

10mg · 25mg

Empagliflozin tablets for type 2 diabetes and heart failure. They lower blood sugar by letting the kidneys remove it in urine.

From$4.68/ tabletView

Sartel

Telmisartan

40mg

Telmisartan tablets for high blood pressure and cardiovascular risk. It blocks a hormone that narrows blood vessels.

From$0.81/ tabletView

Key points

  • Risk factors can work together, so cardiovascular risk is considered as an overall picture rather than as one health measure.
  • Blood pressure and metabolism are health areas linked with the medicines grouped under this topic.
  • Prevention may include lifestyle changes and medicines, depending on a person’s health needs.

Medicines listed for cardiovascular risk reduction

The listed products contain Ramipril, Empagliflozin and telmisartan. Ramipril and telmisartan affect blood pressure, while empagliflozin affects glucose handling and metabolism. These ingredients are listed in this catalogue for cardiovascular risk reduction, relating to the heart and blood vessels.

Further reading